Healthcare | April 08, 2026
WHO updates global guidelines to combat opioid crisis
Opioid dependence remains a major driver of death and disease worldwide
Opioid dependence remains a major driver of death and disease worldwide
Biopharma companies face persistent hurdles in cell line development, including long timelines, low yields, and high failure rates for novel molecules
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
New filtration lines will boost global drug supply and strengthen India’s role in Merck’s manufacturing network
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Subscribe To Our Newsletter & Stay Updated
